Stockreport

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SV [Read more]